Discuss Adamax on glp1chat
Join the forum to discuss research with other members.
At a glance
Adamax is a modified relative of Semax studied for possible effects on nerve-cell signaling. The change to the molecule is intended to alter how it behaves in the body, but studies of Semax do not establish the same effects for Adamax itself.
Semax is used as a starting point for the idea: alter a nerve-signaling peptide and see whether its effects last or reach tissue differently. A chemical change can also change which targets the molecule reaches, so Adamax has to be studied on its own. Its proposed uses in focus and recovery are research questions, not results that can be borrowed from Semax studies.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
Cognition and neuronal resilience are research themes in the cited material. Check whether each experiment actually tested Adamax or another peptide.[4][7][8]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Adamax.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 300 µg (0.3 mg) | 9 units (0.09 mL) |
| Weeks 3–4 | 500 µg (0.5 mg) | 15 units (0.15 mL) |
| Weeks 5–6 | 750 µg (0.75 mg) | 23 units (0.23 mL) |
| Weeks 7–8 | 1000 µg (1.0 mg) | 30 units (0.30 mL) |
Frequency: Inject once daily subcutaneously. This schedule uses the largest practical dilution (3.0 mL) to keep per‑injection units readable. For the 300 µg starting dose (9 units = 0.09 mL), consider using 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support cognitive enhancement, neuroprotection, and neuroplasticity via BDNF upregulation[4][5].
- Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired), followed by an equal off‑cycle period.
- Dose Range: 300–1000 µg daily with gradual titration (500 µg is typical mid‑range).
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 300 µg daily for 2 weeks (Week 1–2); allows adaptation to peptide effects.
- Increase: 500 µg daily (Week 3–4), then 750 µg (Week 5–6).
- Maintenance: 1000 µg daily (Week 7+) for continued nootropic support.
- Frequency: Once per day (subcutaneous), preferably morning for consistency.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks with careful monitoring.
- Off‑Cycle: Equal duration break (e.g., 8 weeks on, 8 weeks off) to prevent tolerance.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall to avoid foaming.
- Gently swirl or roll the vial until powder fully dissolves (do not shake vigorously).
- Label with reconstitution date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality and potency.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; keep in original packaging to minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1–2 weeks for optimal potency.
- Avoid Freeze–Thaw: Do not refreeze reconstituted solution; freeze–thaw cycles denature peptides.
- Allow lyophilized vials to reach room temperature before opening to reduce condensation.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[10][10].
- Clean the vial stopper with an alcohol swab and allow to dry (~10 seconds).
- Draw the calculated dose into a sterile insulin syringe; remove air bubbles by gently tapping the syringe.
- Clean the injection site (abdomen, thigh, or upper arm) with a fresh alcohol swab; allow to dry.
- Pinch a fold of skin (~1 inch) between thumb and forefinger to elevate subcutaneous tissue.
- Insert the needle at 45–90° into the skinfold[10]; inject slowly and steadily (do not aspirate).
- Withdraw the needle and apply gentle pressure with a clean gauze pad; do not massage the site aggressively.
- Rotate injection sites systematically to prevent lipohypertrophy and ensure consistent absorption[11].
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Adamax, 10 mg each):
- 8 weeks (gradual dosing): 4 vials (total ~35.7 mg used)
- 12 weeks (gradual dosing): 7 vials (total ~60.2 mg used)
- 16 weeks (gradual dosing): 9 vials (total ~88.2 mg used)
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
Note: For Week 1–2 dosing (9 units), consider 30‑unit or 50‑unit syringes for easier measurement precision.
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 12 weeks (7 vials): 21 mL → 3 × 10 mL bottles
- 16 weeks (9 vials): 27 mL → 3 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 01
Research publication
PubMed — Semax: structure, mechanism, and therapeutic potential (ACTH analog overview) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 02
Research publication
PMC (NCBI) — ACTH(4–10) analogs: neuroprotective and cognitive effects (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
Journal of Neurochemistry (2006) — Semax binds specific brain sites and increases BDNF protein in rat basal forebrain (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Research publication
PubMed — Semax effects on dopamine and serotonin neurotransmission (mood and cognition) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 08
Research publication
PubMed — Neuroprotective effects of Semax in cerebral ischemia models (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
PubMed — Clinical safety and tolerability of Semax in human studies (no major adverse effects) (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 10
Public health resource
MedlinePlus — Subcutaneous injections: patient instructions and technique overview (opens in a new tab)medlineplus.gov
Back to overview ↑ - 11
Public health resource
NCBI Bookshelf — Injection best practices: site rotation, aseptic technique, and administration protocols (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.